
    
      This is a phase IIb, open-label, single arm study assessing the safety and efficacy of
      BPI-7711 (180 mg, orally, once daily) in China with a confirmed diagnosis of EGFR sensitizing
      mutation positive and T790M mutation+ unresectable, locally advanced or metastatic NSCLC, who
      have progressed on prior EGFR-TKIs treatment. The primary objective of the study is to assess
      the efficacy of BPI-7711 by assessment of ORR according to RECIST 1.1 by an Independent
      Central Review.
    
  